Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.04 Billion USD | -21.7% |
| 2022 | 593.2 Million USD | -7.44% |
| 2021 | 640.9 Million USD | 7.25% |
| 2020 | 597.6 Million USD | 7.02% |
| 2019 | 558.4 Million USD | 50.8% |
| 2018 | 370.3 Million USD | 53.73% |
| 2017 | 240.88 Million USD | -4.4% |
| 2016 | 251.97 Million USD | -16.69% |
| 2015 | 302.45 Million USD | 10.52% |
| 2014 | 273.67 Million USD | 31.69% |
| 2013 | 207.81 Million USD | 5.9% |
| 2012 | 196.24 Million USD | -1.44% |
| 2011 | 199.11 Million USD | 20.31% |
| 2010 | 165.5 Million USD | 11.54% |
| 2009 | 148.37 Million USD | 29.53% |
| 2008 | 114.54 Million USD | 4.6% |
| 2007 | 109.51 Million USD | 21.54% |
| 2006 | 90.1 Million USD | 76.07% |
| 2005 | 51.17 Million USD | 26.54% |
| 2004 | 40.44 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 16.2 Million USD | -98.14% |
| 2001 | 869.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 104.6 Million USD | 5.02% |
| 2024 Q1 | 99.6 Million USD | -14.65% |
| 2023 Q4 | 116.7 Million USD | -0.77% |
| 2023 Q1 | 158.1 Million USD | -6.84% |
| 2023 Q2 | 133.5 Million USD | -15.56% |
| 2023 FY | 464.5 Million USD | -21.7% |
| 2023 Q3 | 117.6 Million USD | -11.91% |
| 2022 Q4 | 169.7 Million USD | 27.21% |
| 2022 Q2 | 144.9 Million USD | -0.21% |
| 2022 Q3 | 133.4 Million USD | -7.94% |
| 2022 Q1 | 145.2 Million USD | -24.06% |
| 2022 FY | 593.2 Million USD | -7.44% |
| 2021 Q4 | 191.2 Million USD | 30.78% |
| 2021 FY | 640.9 Million USD | 7.25% |
| 2021 Q1 | 148.3 Million USD | -5.3% |
| 2021 Q2 | 155.2 Million USD | 4.65% |
| 2021 Q3 | 146.2 Million USD | -5.8% |
| 2020 Q3 | 174.9 Million USD | 25.92% |
| 2020 Q2 | 138.9 Million USD | 9.2% |
| 2020 Q1 | 127.2 Million USD | -15.09% |
| 2020 FY | 597.6 Million USD | 7.02% |
| 2020 Q4 | 156.6 Million USD | -10.46% |
| 2019 Q3 | 133.1 Million USD | -10.91% |
| 2019 FY | 558.4 Million USD | 50.8% |
| 2019 Q1 | 126 Million USD | -13.88% |
| 2019 Q2 | 149.4 Million USD | 18.57% |
| 2019 Q4 | 149.8 Million USD | 12.55% |
| 2018 Q2 | 64.25 Million USD | -7.23% |
| 2018 Q4 | 146.3 Million USD | 84.93% |
| 2018 FY | 370.3 Million USD | 53.73% |
| 2018 Q1 | 69.25 Million USD | -1.73% |
| 2018 Q3 | 79.11 Million USD | 23.13% |
| 2017 Q3 | 57.16 Million USD | -0.79% |
| 2017 FY | 240.88 Million USD | -4.4% |
| 2017 Q1 | 55.62 Million USD | -10.96% |
| 2017 Q2 | 57.61 Million USD | 3.58% |
| 2017 Q4 | 70.47 Million USD | 23.29% |
| 2016 FY | 251.97 Million USD | -16.69% |
| 2016 Q2 | 79.49 Million USD | 7.52% |
| 2016 Q4 | 62.47 Million USD | -7.96% |
| 2016 Q3 | 67.87 Million USD | -14.62% |
| 2016 Q1 | 73.93 Million USD | -5.74% |
| 2015 Q4 | 78.44 Million USD | 6.83% |
| 2015 Q1 | 73.19 Million USD | 3.28% |
| 2015 FY | 302.45 Million USD | 10.52% |
| 2015 Q2 | 77.39 Million USD | 5.74% |
| 2015 Q3 | 73.42 Million USD | -5.13% |
| 2014 Q4 | 70.87 Million USD | -4.87% |
| 2014 FY | 273.67 Million USD | 31.69% |
| 2014 Q2 | 67.95 Million USD | 12.61% |
| 2014 Q1 | 60.34 Million USD | 8.94% |
| 2014 Q3 | 74.49 Million USD | 9.63% |
| 2013 Q2 | 50.77 Million USD | 0.05% |
| 2013 Q3 | 50.89 Million USD | 0.22% |
| 2013 FY | 207.81 Million USD | 5.9% |
| 2013 Q4 | 55.39 Million USD | 8.84% |
| 2013 Q1 | 50.75 Million USD | -8.42% |
| 2012 Q1 | 45.73 Million USD | -3.97% |
| 2012 Q2 | 48.54 Million USD | 6.13% |
| 2012 Q3 | 46.54 Million USD | -4.11% |
| 2012 FY | 196.24 Million USD | -1.44% |
| 2012 Q4 | 55.42 Million USD | 19.07% |
| 2011 Q1 | 52.97 Million USD | 3.29% |
| 2011 Q3 | 46.64 Million USD | -10.06% |
| 2011 Q2 | 51.86 Million USD | -2.09% |
| 2011 FY | 199.11 Million USD | 20.31% |
| 2011 Q4 | 47.63 Million USD | 2.11% |
| 2010 Q1 | 36.11 Million USD | -4.7% |
| 2010 Q4 | 51.28 Million USD | 22.55% |
| 2010 FY | 165.5 Million USD | 11.54% |
| 2010 Q3 | 41.84 Million USD | 15.44% |
| 2010 Q2 | 36.25 Million USD | 0.38% |
| 2009 Q3 | 38.53 Million USD | -3.78% |
| 2009 Q2 | 40.05 Million USD | 25.62% |
| 2009 FY | 148.37 Million USD | 29.53% |
| 2009 Q1 | 31.88 Million USD | 13.77% |
| 2009 Q4 | 37.89 Million USD | -1.67% |
| 2008 Q4 | 28.02 Million USD | -8.83% |
| 2008 Q1 | 23.53 Million USD | -18.66% |
| 2008 Q2 | 32.24 Million USD | 37.01% |
| 2008 FY | 114.54 Million USD | 4.6% |
| 2008 Q3 | 30.74 Million USD | -4.66% |
| 2007 Q1 | 26.76 Million USD | -12.28% |
| 2007 Q4 | 28.93 Million USD | 4.03% |
| 2007 Q3 | 27.81 Million USD | 6.98% |
| 2007 Q2 | 26 Million USD | -2.85% |
| 2007 FY | 109.51 Million USD | 21.54% |
| 2006 Q1 | - USD | 100.0% |
| 2006 FY | 90.1 Million USD | 76.07% |
| 2006 Q4 | 30.51 Million USD | 53.59% |
| 2006 Q3 | 19.86 Million USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | 51.17 Million USD | 26.54% |
| 2005 Q1 | - USD | 100.0% |
| 2005 Q4 | -82.77 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | -70.54 Million USD | 0.0% |
| 2004 FY | 40.44 Million USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2002 FY | 16.2 Million USD | -98.14% |
| 2001 FY | 869.5 Million USD | 0.0% |
| 2001 Q4 | 228.5 Million USD | -37.17% |
| 2001 Q3 | 363.7 Million USD | -26.66% |
| 2001 Q2 | 495.9 Million USD | 64.7% |
| 2001 Q1 | 301.1 Million USD | 31.77% |
| 2000 Q4 | 228.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 616.19 Million USD | -69.428% |
| Bausch Health Companies Inc. | 5.23 Billion USD | 80.057% |
| Catalent, Inc. | 1.7 Billion USD | 38.66% |
| Elanco Animal Health Incorporated | 1.61 Billion USD | 35.236% |
| Perrigo Company plc | 1.52 Billion USD | 31.698% |
| Teva Pharmaceutical Industries Limited | 4.45 Billion USD | 76.545% |
| Zoetis Inc. | 2.76 Billion USD | 62.242% |